updated guidelines emphasize the benefits of early treatment with antiretroviral therapy against HIV infection

human checkThe Department of Health and Human Services updated its Guidelines for the use of antiretroviral therapy in HIV-Infected Children-1, adults and adolescents to reflect the conclusions obtained from the START study and TEMPRANO studies demonstrating the benefits of the clinical picture people who have had an early initiation of antiretroviral therapy (ART) with a pre-treatment of these patients, even those with CD4 cell counts and above 500 cells / mm3.

START study results were first announced in May last year and presented at the International AIDS Society Conference in July 2015. Participants in the trials with up CD4 cell counts 500 cells / mm3They were randomly assigned to start treatment immediately or wait until their therapies CD4 cell counts fell below 350 cells / mm3or when they develop symptoms of AIDS.

The study showed that people in the immediate treatment group were 57% less likely to experience a serious outcome with events related to AIDS, not related to AIDS and death, compared with deferred therapy groups. People treated early not only had a 72% lower risk of suffering with events related to AIDS, but also a reduction of 39% by events unrelated to AIDS, including cancer!

The TEMPRANO study findings presented at last year's conference on retroviruses and opportunistic infections, also showed that the onset of ART in a CD4 count above 500 cells / mm3reduced the risk of severe disease and death compared to the beginning of delayed treatment.

The main changes to the guidelines

  • The DHHS Panel increased the strength and the special stage for "A1" to the recommendation that all people diagnosed with HIV should start art regardless of CD4 count.
  • The early treatment recommendation for patients with diagnosis of acute or recent infection with HIV was reinforced, also given a rating of "A1".
  • Although they have not been included in the study START or TEMPRANO, the panel decided the recommendation to treat all patients with HIV should include them; the panel recommends that post-pubescent adolescents should be treated according to adult guidelines and prepubertal children should be treated in accordance with pediatric guidelines.

The panel reinforced its emphasis on immediate treatment for older adults living with HIV, since these people are at higher risk of being affected by serious complications unrelated to AIDS and an immune response to potentially dull ART.

In November 2015 the panel added the newly approved Genvoya formulation - the first scheme to contain the "new" (the quotes are the editor) and safer tenofovir alafenamide (TAF) - as a recommended option for first-line treatment.

Complete and updated guidelines are available online athttps://aidsinfo.nih.gov/guidelines. The panel welcomes feedback on the revised guidelines to 12 February 2016 (send toContactUs@aidsinfo.nih.gov).

Written by Liz Highleyman. Translated by Claudio Souza on the night of 05 / 02 / 2016 the originalDUpdated Antiretroviral Therapy Guidelines Emphasize Benefits of Early HIV TreatmentReview, Mara Macedo.

Reference

Panel on antiretroviral HHS guidelines for adults and adolescents.Guidelines for the use of antiretroviral therapy in HIV-Infected Children-1 adults and adolescents(Opens another site in English - I promise Translate). 28 January 2016.

Another source

Aidsinfo. HHS adult and adolescents updated antiretroviral treatment guidelines released. Press office. 28 January 2016.

anguished note Soropositivo.org editor | Yes, I know. These studies are needed. I just wonder if it is necessary that there are deaths, and these dead people are transformed into statistical data. Although I have not infirm connection with any NGO and no commitment to any laboratory (The site is maintained with my money and my job) I question the medical ethics that studies lives and stratifies deaths "a greater good".

How many of us still have to die in order to reach to a vaccine or a cure. Because the Gilead squeezed Tenofovir to the penny before launching Genoya and how often it will still be done.

Glad tidings, you who are diagnosed to be suffering now and did not live moments like me, of "therapeutic holidays" and now I feel injured in lifespan and quality of life for something that today can only be seen as a huge monstrosity and a fierce lust on to retain the $ Recur. You will have a better and longer life. Remember you see to our graves, lay flowers and some pills. And if possible, also a prayer.